LRMR News and Press, Larimar Therapeutics Inc. From 10/15/25

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or “the Company”) (NASDAQ: LRMR ) for violations of the securities laws. The investi...

New York, New York--(Newsfile Corp. - October 9, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Larimar Therapeutics, Inc. ("Larimar Therapeutics, Inc.") (NASDAQ: LRMR) concerning possible violations of federal securities laws. Larimar issued a press re...

2025-10-01 12:03:54 ET Larimar Therapeutics, Inc. (NASDAQ: LRMR) is one of today’s top gainers. The company’s shares have moved 30.34% on the day to $4.21. Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare dis...

2025-09-30 07:53:43 ET Joel Beatty from Robert W. Baird issued a price target of $7.00 for LRMR on 2025-09-30 11:24:41. The adjusted price target was set to $7.00. At the time of the announcement, LRMR was trading at $3.38. The overall price target consensus is at $19.00...

2025-09-29 14:55:11 ET Larimar Therapeutics, Inc. (LRMR) Discusses On The Nomlabofusp Program For The Treatment of Friedreich’s Ataxia Conference Call... Read the full article on Seeking Alpha For further details see: Larimar Therapeutics, Inc. (LRMR) Discusses On The...

2025-09-29 14:47:38 ET Larimar Therapeutics, Inc. - Special Call Company Participants Carole Ben-Maimon - CEO, President & Director Conference Call Participants Alexandra Folias Yatin Suneja - Guggenheim Securities, LLC, Research Division Joor...

A look at the top 10 most actives in the United States Dragonfly Energy Holdings Corp (DFLI) rose 39.4% to $0.7295 on volume of 77,666,812 shares Tilray Brands Inc. (TLRY) rose 34.3% to $1.545 on volume of 71,705,631 shares PLUS THERAPEUTICS Inc. (PSTV) rose 18.6% to $0.7316 on volume of 56...

In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL study Increases in skin FXN levels with short- and long-term daily nomlabo...

BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss updates ...

2025-08-14 07:27:00 ET More on Larimar Therapeutics Larimar Therapeutics prices $60M stock offering Larimar Therapeutics drops 20% as it announces public offering Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earnings data for Larimar...